Top Markets
Coin of the day
GBS Inc. GBS Inc.

GBS Inc.

GBS
Rangering i aksjer #33721
Operating across North America and the Asia-Pacific region, GBS Inc.... Operating across North America and the Asia-Pacific region, GBS Inc. specializes in biosensor diagnostic technology. Its key product is the Saliva Glucose Biosensor, an innovative organic thin-film transistor designed for diabetes management that quantifies glucose levels directly from saliva. The company is also actively advancing a SARS-CoV-2 Biosensor, intended as a supplementary diagnostic tool to existing RNA virus detection tests, and is constructing a broad biosensor platform covering diagnostic modalities such as biochemistry, immunology, tumor markers, hormones, and nucleic acids. GBS Inc. maintains a research agreement with the Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic solutions. Founded in 2016 and headquartered in New York, New York, the company adopted its current name, GBS Inc., in September 2019, having previously operated as Glucose Biosensor Systems (Greater China) Holdings, Inc. It operates as a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
Aksjekurs
$0.4732
Sist synkronisert: 2022-10-26
Markedsverdi
$7.05M
Endring (1 dag)
-0.03%
Endring (1 år)
0.00%
Land
US
Handel GBS Inc. (GBS)

Kategori

Inntekter for GBS Inc. (GBS)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til GBS Inc. er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for GBS Inc. fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$46.59B -
US
$25.84B -
US
$35.48B -
IE
$21.00B -
US
$6.51B -
US